A Sampling of Post-modern American Writers

Staggs, Kenneth W. 한국영어영문학회 1983 영어 영문학 Vol.29 No.2

고별담화: 요한복음 13-17장

Frank Stagg,문종선 한영신학대학교 출판부 2010 한영연구논문 Vol.2 No.-

Restraint Use in Hospitals: A Quality and Safety Issue in Need of Attention

Vincent S. Staggs 한국성인간호학회 2021 성인간호학회 학술대회 Vol.2021 No.8

Uranium-Incorporated Iron (Oxyhydr) Oxide in Geodisposal Systems: The Effects of Biogeochemical Perturbations on Long-Term Stability

Samuel Shaw,Olwen Stagg,Katherine Morris,Liam Abrahamsen-Mills,Luke Townsend,Thomas S. Niell,J. Frederick W. Mosselmans 한국방사성폐기물학회 2023 한국방사성폐기물학회 학술논문요약집 Vol.21 No.2

In all geodisposal scenarios it is key to understand the interaction of radionuclides with mineral particles during their formation/recrystallisation. Studying processes at the molecular scale provides insight into long-term radionuclide behaviour. Uranium is a significant radionuclide in higher activity wastes destined for geological disposal, and iron (oxyhydr) oxides (e.g. goethite, ?-FeOOH). are ubiquitous in and around these systems, formed via processes including metal corrosion and microbially induced reactions. There are numerous reports of uranium-incorporation into iron (oxyhydr) oxides, therefore it has been suggested that they may be a barrier to uranium migration in geodisposal systems. However, long-term stability of these phases during environmental perturbations are unexplored. Specifically, U-incorporated iron (oxyhydr) oxide phases may interact with Fe(II) and sulphide from biological or geological origin. Firstly, electron transfer occurs between adsorbed Fe(II) and iron oxyhydroxides, with potential for changes in the speciation of incorporated uranium e.g. oxidation state changes and/or release. Secondly, on exposure to aqueous sulfide, iron (oxyhydr) oxides undergo reductive dissolution and recrystallisation to iron sulphides. Understanding the fate of incorporated uranium during these process in key to understanding its long term behaviour in subsurface systems. A series of experimental studies were undertaken where U(VI)-goethite was synthesized then reacted with either aqueous Fe(II) or S(-II), and the system monitored over time using geochemical analysis and X-ray absorption spectroscopy (XAS) techniques e.g. U LIII-edge and MIV-edge HERFD-XANES. Reaction with aqueous Fe(II) resulted in electron transfer between Fe(II) and U(VI)-goethite, with > 50% U(VI) reduced to U(V). XAS analysis revealed that U remained within the goethite structure, and electron transfer only occurred within the outermost atomic layers of goethite. which led to U reduction. Rapid reductive dissolution of U(VI)-goethite occurred on reaction with sulfide at pH7. A transient release of aqueous U was observed during the first day, likely due to uranyl(VI)-persulfide species. However, U was retained in the solid phase in the longer term. In contrast, the sulfidation of U adsorbed to ferrihydrite at pH 12.2 led to the immediate release of U (< 10% Utotal) associated with a colloidal erdite (NaFeS2·2H2O) phase. Moreover, in the bulk phase the surface of ferrihydrite was passivated by sulfide, and U was found to have been trapped within surface associated erdite-like fibres. Overall, these studies further understanding of the long-term behaviour of U-incorporated iron (oxyhydr)oxides supporting the overarching concept of iron (oxyhydr) oxides acting as a barrier to U migration.

Gate Drive Unit for a Dual-GCT

T. Butschen,G. Sarriegi Etxeberria,H. Stagge,R.W. De Doncker 전력전자학회 2011 ICPE(ISPE)논문집 Vol.2011 No.5

Today, Gate Commutated Thyristors (GCTs) are used in high power converters due to their high current switching and high voltage blocking capabilities. The optimization of these power switches is of utmost importance in order to increase the efficiency of the complete system. To achieve that, a novel semiconductor device was introduced, the Dual-GCT [1][2]. In this paper, a Gate Drive Unit (GDU) for the Dual-GCT is presented. Compared to standard IGCTs a size reduction of one third is achieved with equal switching capabilities. Additionally, extended functionalities that are usually not implemented in commercial drivers is introduced to obtain a better performance during the operation of the semiconductor device. Furthermore a Short Circuit Protection is described in detail which detects the short circuit in around 80 ㎱.

Immune evasion in cancer: Mechanistic basis and therapeutic strategies

Vinay, D.S.,Ryan, E.P.,Pawelec, G.,Talib, W.H.,Stagg, J.,Elkord, E.,Lichtor, T.,Decker, W.K.,Whelan, R.L.,Kumara, H.M.C.S.,Signori, E.,Honoki, K.,Georgakilas, A.G.,Amin, A.,Helferich, W.G.,Boosani, C. Saunders Scientific Publications ; Academic Press 2015 SEMINARS IN CANCER BIOLOGY Vol.35 No.suppl

Cancer immune evasion is a major stumbling block in designing effective anticancer therapeutic strategies. Although considerable progress has been made in understanding how cancers evade destructive immunity, measures to counteract tumor escape have not kept pace. There are a number of factors that contribute to tumor persistence despite having a normal host immune system. Immune editing is one of the key aspects why tumors evade surveillance causing the tumors to lie dormant in patients for years through ''equilibrium'' and ''senescence'' before re-emerging. In addition, tumors exploit several immunological processes such as targeting the regulatory T cell function or their secretions, antigen presentation, modifying the production of immune suppressive mediators, tolerance and immune deviation. Besides these, tumor heterogeneity and metastasis also play a critical role in tumor growth. A number of potential targets like promoting Th1, NK cell, γδ T cell responses, inhibiting Treg functionality, induction of IL-12, use of drugs including phytochemicals have been designed to counter tumor progression with much success. Some natural agents and phytochemicals merit further study. For example, use of certain key polysaccharide components from mushrooms and plants have shown to possess therapeutic impact on tumor-imposed genetic instability, anti-growth signaling, replicative immortality, dysregulated metabolism etc. In this review, we will discuss the advances made toward understanding the basis of cancer immune evasion and summarize the efficacy of various therapeutic measures and targets that have been developed or are being investigated to enhance tumor rejection.

A Gene-Shuffled Glyphosate Acetyltransferase Protein from Bacillus licheniformis (GAT4601) Shows No Evidence of Allergenicity or Toxicity

Delaney, Bryan,Zhang, John,Carlson, Gabrielle,Schmidt, Jean,Stagg, Barb,Comstock, Brad,Babb, Amy,Finlay, Carol,Cressman, Robert F.,Ladics, Greg,Cogburn, Amarin,Siehl, Dan,Bardina, Luda,Sampson, Hugh,H Oxford University Press 2008 Toxicological sciences Vol.102 No.2

<P>The glyphosate acetyltransferase (gat) gene from Bacillus licheniformis was subjected to multiple rounds of gene shuffling to optimize kinetics of corresponding GAT proteins to acetylate the herbicide active ingredient glyphosate. Genetically modified soybeans expressing the gat4601 gene (356043 soybeans) are tolerant to the application of glyphosate. The current manuscript reports the outcome of the allergenicity and toxicity assessment for the GAT4601 protein. Bioinformatic comparison of the amino acid sequence of GAT4601 did not identify similarities to known allergenic or toxic proteins. In vitro studies conducted with heterologously produced GAT4601 protein demonstrated that it was rapidly degraded in simulated gastric fluid containing pepsin (< 30 s) and in simulated intestinal fluid containing pancreatin (< 2 min) and completely inactivated at temperatures above 56 degrees C. The GAT4601 protein expressed in planta is not glycosylated and similar protein profiles were observed in flour extracts from 356043 soybeans and nontransgenic near isoline comparator soybeans (Jack) using serum from soy allergic persons. No evidence of adverse effects was observed in mice following acute oral exposure to 2000 mg/kg of GAT4601 protein or in a repeated dose dietary exposure study at doses of 800-1000 mg/kg/day. This comprehensive assessment demonstrates that the GAT4601 protein does not present a risk for adverse effects in humans when used in the context of agricultural biotechnology.</P>